FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-OMB Number: 0104 Estimated average burden hours per response:

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MILLER RICHARD A MD	Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 02/04/2021 3. Issuer Name and Ticker or Trading Symbol Bolt Biotherapeutics, Inc. [BOLT]					
(Last) (First) (Middle) C/O BOLT BIOTHERAPEUTICS, INC. 900 CHESAPEAKE DRIVE			4. Relationship of Reporting Issuer (Check all applicable) X Director Officer (give	10% O	wner	5. If Amendment, Filed (Month/Day/ 6. Individual or Joi (Check Applicable	Year) int/Group Filing
(Street) REDWOOD CA 94063 (City) (State) (Zip)	-		title below)	below)		A Person	by One Reporting by More than One Person
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr.			4. Nature of Indirect Beneficial Ownership (Instr. 5)	
			4)	(D) or Ir	direct		-,
Common Stock			,	(D) or Ir	direct : 5)		-,
		Derivative	4)	(D) or Ir (I) (Instr	ed		
		Derivative	15,602 Securities Beneficia	(D) or Ir (I) (Instr Ily Own ble sec	ed urities)	se Form:	6. Nature of Indirect Beneficial Ownership (Instr.
(e.g	., puts, cal 2. Date Exerc Expiration Da	Derivative	15,602 Securities Beneficiants, options, converti 3. Title and Amount of Secunderlying Derivative Secunders. 4)	(D) or Ir (I) (Instr Ily Own ble sec	ed urities)	Ownership Se Form: Direct (D)	6. Nature of Indirect Beneficial

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on the one-month anniversary of July 2, 2019 (the "Vesting Commencement Date") and 1/48th of the shares shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a service provider to the Issuer through each such date.

Remarks:

Exhibit 24 - Power of Attorney

02/04/2021 Attorney-in-Fact

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of William Quinn of Bolt Biotherapeutics, Inc. (the "Company") and John McKenna, Julia Stark, Colleen Badgley, Michael Perretta, Tess Morgan and Brian Woodard of Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation thereunder;
- (2) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such Forms with the SEC and any stock exchange, self-regulatory association or any other authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Dated: January 15, 2021

By: /s/ Richard A. Miller, M.D. Richard A. Miller, M.D. Signature Printed Name